249647-24-3

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
3-Bromo-4-iodobenzoic acid methyl ester is used as a building block for the synthesis of biologically active compounds, contributing to the development of new pharmaceuticals with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Bromo-4-iodobenzoic acid methyl ester is used as a key intermediate for the creation of complex organic molecules, facilitating the synthesis of a wide range of chemical entities.
Used in Specialty Chemicals and Materials Production:
3-Bromo-4-iodobenzoic acid methyl ester is utilized in the production of specialty chemicals and materials, leveraging its unique reactivity and molecular structure to develop new compounds with specific properties for various applications.

InChI:InChI=1/C8H6BrIO2/c1-12-8(11)5-2-3-7(10)6(9)4-5/h2-4H,1H3

Upstream product

• 619-44-3 methyl 4-iodobenzoate 
• 67-56-1 methanol 
• 249647-25-4 3-bromo-4-iodobenzoic acid 
• 6311-37-1 4-amino-3-bromo-benzoic acid 
• 106896-49-5 methyl 4-amino-3-bromobenzoate 

Downstream Products

• 1039420-35-3 methyl 3-bromo-4-(4-oxobutyl)benzoate 
• 1057977-13-5 4,4'-(1,2-ethynediyl)bis(3-bromobenzoic acid) dimethyl ester 
• 1092491-66-1 C₁₇H₁₅BrO₃ 
• 1149684-26-3 methyl 3-bromo-4-(5-oxopentyl)benzoate 
• 1150112-11-0 methyl 3-bromo-4-[(trimethylsilyl)ethynyl]benzoate 
• 1378284-27-5 methyl 3-[(4-methoxyphenyl)ethynyl]-4-[(trimethylsilyl)-ethynyl]benzoate 
• 1383604-50-9 methyl 4-ethynyl-3-(thiophen-2-ylethynyl)benzoate 
• 1401615-53-9 methyl 3-(thiophen-2-ylethynyl)-4-[(trimethylsilyl)ethynyl]benzoate 
• 1383604-51-0 methyl 4-ethynyl-3-(pent-1-ynyl)benzoate 
• 1383604-54-3 dimethyl 2-(4-methoxybenzyl)-4-(4-methoxyphenyl)-2,3-dihydro-1H-benzo[g]indazole-1,7-dicarboxylate 
• 1383604-55-4 dimethyl 3-isopropyl-2-(4-methoxybenzyl)-4-(4-methoxyphenyl)-2,3-dihydro-1H-benzo[g]indazole-1,7-dicarboxylate 
• 1383604-56-5 dimethyl 2-(4-methoxybenzyl)-4-(thiophen-2-yl)-2,3-dihydro-1H-benzo[g]indazole-1,7-dicarboxylate 
• 1383604-57-6 dimethyl 3-isopropyl-2-(4-methoxybenzyl)-4-(thiophen-2-yl)-2,3-dihydro-1H-benzo[g]indazole-1,7-dicarboxylate 
• 1383604-58-7 dimethyl 2-(4-methoxybenzyl)-4-propyl-2,3-dihydro-1H-benzo[g]indazole-1,7-dicarboxylate 

Relevant academic research and scientific papers

Post synthetic exchange enables orthogonal click chemistry in a metal organic framework

Biphenyl-4,4′-dicarboxylic acid derivatives containing either azide or acetylene functional groups were inserted into UiO-67 metal organic frameworks (MOFs) via post synthetic linker exchange. Sequential and orthogonal click reactions could be performed o

SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS

The invention recites spirocyclic isoxazoline derivatives of Formula (V.1), Formula (V.2), Formula (V.1.1), and Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, processes for making, and their use as a parasi

ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS

This invention recites isoxazoline substituted azetidine derivatives of Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, and their use as a parasiticide in mammals and birds. R1a, R1b, R1c, R2, R3, R4, R6, and n are as described herein.

Design and synthesis of a novel class of CK2 inhibitors: Application of copper- and gold-catalysed cascade reactions for fused nitrogen heterocycles

Two classes of fused nitrogen heterocycles were designed as CK2 inhibitor candidates on the basis of previous structure-activity relationship (SAR) studies. Various dipyrrolo[3,2-b:2′,3′-e]pyridine and benzo[g]indazole derivatives were prepared using transition-metal-catalysed cascade and/or multicomponent reactions. Biological evaluation of these candidates revealed that benzo[g]indazole is a promising scaffold for potent CK2 inhibitors. The inhibitory activities on cell proliferation of these potent CK2 inhibitors are also presented.

BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065

The invention provides compounds of formula wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1

BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066

The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.

Asymmetric palladium-catalyzed intramolecular α-arylation of aldehydes

(Chemical Equation Presented) Phoxy ligand: The first catalytic method for the asymmetric palladium-catalyzed intramolecular α-arylation of α-branched aldehydes was developed (see scheme). This process is distinguished by the high yields and enantioselectivities that can be obtained, making this protocol a useful synthetic tool for further applications.

Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70

A series of 1,2,4-oxadiazole analogues has been shown to be potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70, a potential therapeutic target for immune suppression. These compounds typically are 200- 400-fold more potent than the native,